Claims for Patent: 10,426,777

Summary for Patent: 10,426,777

Title:	Methods used to treat cancer
Abstract:	The invention encompasses methods of treating a patient with cancer, such as glioblastoma. The methods may include the administration of one or more pharmaceutical compositions that are capable of inhibiting TROY to treat the patient with cancer.
Inventor(s):	Tran; Nhan (Phoenix, AZ), Loftus; Joseph C. (Scottsdale, AZ), Dhruv; Harshil (Phoenix, AZ)
Assignee:	The Translational Genomics Research Institute (Phoenix, AZ) Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	15/842,846
Patent Claims:	1. A pharmaceutical composition comprising: a first active ingredient, wherein the first active ingredient is propentofylline or a pharmaceutically acceptable salt thereof; and a second active ingredient, wherein the second active ingredient is a chemotherapeutic agent selected from the group consisting of: cis-diamminedichloro platinum (II) (cisplatin), doxorubicin, 5-fluorouracil, paclitaxel, topoisomerase inhibitor, and a targeted-therapy drug. 2. The pharmaceutical composition of claim 1, wherein the topoisomerase inhibitor is selected from the group consisting of: etoposide, teniposide, irinotecan, and topotecan. 3. The pharmaceutical composition of claim 1, wherein the targeted-therapy drug is selected from the group consisting of: an inhibitor of signaling through TROY (TNFRSF19) activation, temozolomide, bevacizumab, gefitinib, erlotinib, cetuximab, lapatinib, panitumumab, vandetanib, afatinib, icotinib, zalutumumab, nimotuzumab, and matuzumab. 4. The pharmaceutical composition of claim 3, wherein the inhibitor of signaling through TROY (TNFRSF19) activation is selected from the group consisting of: Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, and Dock7 inhibitors. 5. The pharmaceutical composition of claim 1, wherein the second active ingredient is selected from the group consisting of: Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, temozolomide, and bevacizumab. 6. The pharmaceutical composition of claim 1, wherein the second active ingredient is selected from the group consisting of: an antibody against TROY that inhibits TROY, Pyk2 shRNA, Rac1 siRNA, Dock180 siRNA, Dock7 siRNA, temozolomide, and bevacizumab. 7. The pharmaceutical composition of claim 1, wherein the second active ingredient is temozolomide. 8. The pharmaceutical composition of claim 1 further comprising at least one pharmaceutically acceptable carrier. 9. The pharmaceutical composition of claim 1, wherein the composition treats glioblastoma. 10. The pharmaceutical composition of claim 8, wherein the propentofylline or a pharmaceutically acceptable salt thereof is in an amount sufficient to inhibit TROY expression, but the amount is less than sufficient to substantially reduce viability of glioblastoma cells. 11. The pharmaceutical composition of claim 9, further comprising an anxiolytic agent. 12. The pharmaceutical composition of claim 1, further comprising an antiemetic ingredient. 13. The pharmaceutical composition of claim 1, further comprising a hematopoietic colony stimulating factor. 14. The pharmaceutical composition of claim 1, further comprising an analgesic agent.

Details for Patent 10,426,777

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2029-10-23
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2029-10-23
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2029-10-23
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2029-10-23